Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy

Berdiaki, Aikaterini; Neagu, Monica; Giatagana, Eirini-Maria; Kuskov, Andrey; Tsatsakis, Aristidis; Tzanakakis, George N.; Nikitovic, Dragana

doi:10.3390/biom11030395

Cited by 34 publications

(19 citation statements)

References 270 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The glycosaminoglycan degradation pathway is mediated by enzymes produced by activated T cells, and it has been reported to be involved in the immune response and regulation of T cell homeostasis. 77,78 On the other hand, purine metabolism especially the adenosine synthesis axis serves as a common path for attenuating T cell activation and can mediate regulatory T cell to suppress immune activity [79][80][81] ; therefore in the TATs compartment, this metabolic pathway is downregulated.…”

Section: (E) Heatmap Shows Differentially Expressed Genes Between Tat...mentioning

confidence: 99%

TCR repertoire and transcriptional signatures of circulating tumour‐associated T cells facilitate effective non‐invasive cancer detection

Chen

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

Section: (E) Heatmap Shows Differentially Expressed Genes Between Tat...mentioning

confidence: 99%

TCR repertoire and transcriptional signatures of circulating tumour‐associated T cells facilitate effective non‐invasive cancer detection

Chen

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

“…Previous efforts in classifying the disease and therapy development had focused on the cellular compartment [96]. However, more recent developments have demonstrated the urgent need to understand the ECM component for tumor characterization and efficient therapy development [89,97].…”

Section: The Non-cellular Tme Compartment In Sarcomasmentioning

confidence: 99%

The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

Tzanakakis

Giatagana

Berdiaki

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Bone sarcomas, mesenchymal origin tumors, represent a substantial group of varying neoplasms of a distinct entity. Bone sarcoma patients show a limited response or do not respond to chemotherapy. Notably, developing efficient chemotherapy approaches, dealing with chemoresistance, and preventing metastasis pose unmet challenges in sarcoma therapy. Insulin-like growth factors 1 and 2 (IGF-1 and -2) and their respective receptors are a multifactorial system that significantly contributes to bone sarcoma pathogenesis. Whereas failures have been registered in creating novel targeted therapeutics aiming at the IGF pathway, new agent development should continue, evaluating combinatorial strategies for enhancing antitumor responses and better classifying the patients that could best benefit from these therapies. A plausible approach for developing a combinatorial strategy is to focus on the tumor microenvironment (TME) and processes executed therein. Herewith, we will discuss how the interplay between IGF-signaling and the TME constituents affects sarcomas’ basal functions and their response to therapy. This review highlights key studies focusing on IGF signaling in bone sarcomas, specifically studies underscoring novel properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. Potential direct and adjunct therapeutical implications of the extracellular matrix (ECM) effectors will also be summarized.

show abstract

“…The sources of MMPs are multiple; therefore, MMPs can be released by stromal cells, tumor cells or circulating cells [ 24 ]. The degradation of the ECM and basement membrane are important events in tumor invasion and metastasis [ 25 ]. Certain proteins in the ECM structure, such as fibronectin and laminin, promote cell migration and angiogenesis [ 26 ].…”

Section: Mmps As Molecular Promoters In Carcinogenesismentioning

confidence: 99%

Current Perspectives on the Role of Matrix Metalloproteinases in the Pathogenesis of Basal Cell Carcinoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common skin malignancy, which rarely metastasizes but has a great ability to infiltrate and invade the surrounding tissues. One of the molecular players involved in the metastatic process are matrix metalloproteinases (MMPs). MMPs are enzymes that can degrade various components of the extracellular matrix. In the skin, the expression of MMPs is increased in response to various stimuli, including ultraviolet (UV) radiation, one of the main factors involved in the development of BCC. By modulating various processes that are linked to tumor growth, such as invasion and angiogenesis, MMPs have been associated with UV-related carcinogenesis. The sources of MMPs are multiple, as they can be released by both neoplastic and tumor microenvironment cells. Inhibiting the action of MMPs could be a useful therapeutic option in BCC management. In this review that reunites the latest advances in this domain, we discuss the role of MMPs in the pathogenesis and evolution of BCC, as molecules involved in tumor aggressiveness and risk of recurrence, in order to offer a fresh and updated perspective on this field.

show abstract

Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy

Cited by 34 publications

References 270 publications

TCR repertoire and transcriptional signatures of circulating tumour‐associated T cells facilitate effective non‐invasive cancer detection

TCR repertoire and transcriptional signatures of circulating tumour‐associated T cells facilitate effective non‐invasive cancer detection

The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

Current Perspectives on the Role of Matrix Metalloproteinases in the Pathogenesis of Basal Cell Carcinoma

Contact Info

Product

Resources

About